Explore NLS Pharmaceutics Ltd.'s February 2025 Form 6-K detailing FDA meeting success for Type 1 Diabetes treatment, showcasing regulatory progress and company compliance.
Explore NLS Pharmaceutics Ltd.'s latest 6-K report detailing a strategic partnership with Kadimastem for innovative diabetes therapies beyond GLP-1. Key insights included.
On Jan 16, 2025, NLS Pharmaceutics Ltd. announced a special meeting for a merger with Kadimastem. This Form 6-K highlights key corporate developments and regulatory compliance.
Discover the key outcomes of NLS Pharmaceutics Ltd.'s extraordinary shareholders' meeting held on January 14, 2025, including approvals and SEC filing insights.
Explore NLS Pharmaceutics Ltd.'s January 2025 Form 6-K detailing a $500,000 fundraising initiative and strategic growth insights.
Explore essential insights from NLS Pharmaceutics Ltd.'s January 7, 2025 Form 6-K report, detailing shareholder meeting outcomes and filing specifics.
This report details NLS Pharmaceutics Ltd.'s December 2024 SEC filing, including merger plans with Kadimastem Ltd. Insights on corporate actions and future financial implications.
NLS Pharmaceutics Ltd. announces an Extraordinary Shareholders’ Meeting on Jan 14, 2025. Key details on voting rights and report filings included.
NLS Pharmaceutics Ltd. filed Amendment No. 1 to Form 6-K, correcting the record date for the January 2025 Extraordinary Shareholders’ Meeting. Key SEC compliance details included.
Explore NLS Pharmaceutics' December 2024 report detailing FDA Pre-IND meeting request for Type 1 Diabetes treatment. Discover key developments and strategic insights.
Explore NLS Pharmaceutics Ltd.'s December 2024 Form 6-K report, detailing the upcoming extraordinary shareholder meeting on January 7, 2025, and SEC compliance.